Professionals 235 Users Online

Injectable Drug Delivery Market

Increasing Prevalence of Chronic Diseases is Driving Growth of the Injectable Drug Delivery Market

Injectable Drug Delivery Market is segmented by Self-injectors, Needle-free Injectors, Auto-Injectors, Wearable Injectors, Insulin Pens, Indication, Non-smart Injectors

Injectable Drug Delivery Market Outlook (2024-2033)

Global revenue from the injectable drug delivery market was about US$ 41.5 Bn in 2022, with the worldwide market estimated to surge ahead at a CAGR of 8.4% to reach a valuation of around US$ 101.2 Bn by the end of 2033.

Market Size (2024)

US$49.1 Bn

Projected Market Value (2033)

US$ 101.2 Bn

Global Market Growth Rate (2024-2033)

8.4%

Market Share of Top 5 Countries

52.8%

According to Persistence Market Research, insulin pens segment of the market based on the product secured a market value of US$ 21.2 Bn in 2022.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Sales Analysis of the Market from 2014 to 2022 Vs Market Outlook for 2022 to 2032

The global market recorded a historic CAGR of 7.4% in the last 8 years from 2014 to 2022.

The market value of the global market was approximately 3.1% of the overall ~US$ 1,358.83 Bn of the global drug delivery market in 2022.

Due to the rising prevalence of the chronic diseases the adoption of the injectable drug delivery has increased in the recent years. Diabetes mellitus is not only a chronic disease, but also augments various other chronic diseases such as cardiovascular diseases (increased threat of heart attack and congestive heart failure), renal failure, hepatic disorders, immunodeficiency, loss of vision, brain & nervous system disorders, and impaired injury healing time.

Due to these life-threatening diseases associated with diabetes the preference for the self-monitoring and diagnosis has increased in the past few years. This points to the increasing use of injectable drug delivery products hence, would impact the market in a positive manner.

According to the International Diabetes Federation, the number of adults falling between the age group of 20-79 years and living with diabetes in 2021 was around 537 million. As per the same entity, by 2030, this number would approximately be 643 million, and by 2045, this number would be around 783 million.

Apart from this, the growing demand for injection devices with increasingly advanced and automated features that support self-administration is expected to drive the growth of the global market. Insulin delivery devices are designed considering patient requirements and usage for self-administration and home-use.

The daily administration of insulin doses is very uncomfortable and stressful for diabetic patients. Patients are therefore looking for novel medicine delivery systems that are painless, secure, simple to use, and economical. Insulin delivery devices such as insulin pens or pumps have advantages over conventional delivery system (injection). Conventional delivery systems require injection up to seven times per day and less accurate in insulin delivery, and result in greater variability in blood glucose level.

On the other hand, insulin pumps or pens deliver insulin accurately and precisely than injections, provide greater flexibility with exercise, meals, and daily schedules, reduce severe low blood glucose episodes, and help to improve quality of life. These advantages over conventional delivery systems are likely to fuel the growth of the market in the near future.

The global market is thus likely to show significant growth over the coming years with a CAGR of 8.4%, and reach a global market size of around US$ 101.2 Bn by 2033.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

How can the Market Grow?

“Increased Formulation of Parenteral Products”

The majority of biologic medications are available as injectable. Due to the rising prevalence of various diseases, there are more biologic drugs in development, hence increasing the number of parenteral medications as well. The rising number of parenteral drugs in the pipeline can be considered an important factor to increase the number of parenteral drugs in the market and this is something that would help in increasing the demand for the injectable drug delivery products.

Apart from this, the market will also see opportunities as a result of the need for patient-controlled drug release. One of the most potential and growing innovations in the drug delivery systems is the patient-controlled delivery systems. Chronic conditions including diabetes, cancer and rheumatoid arthritis are increasing and often require daily self-administered injectable therapies.

Although self-administration of medication seems to be convenient, a number of factors such as dosage management, and needle stick injuries can make it difficult. However, advancements in technologies address these issues and have popularized the use of injectable drug delivery devices for patient-controlled medication.

In addition, the geriatric population is a high-risk population for various chronic diseases. Therefore, the use of the injectable drug delivery products can be linked with the rise in geriatric population, creating lucrative opportunities for this market.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Are There Any Barriers That Can Affect the Growth of the Market in Any Way?

High Operational Costs Associated with Manufacturing

Manufacturing injectable drug delivery products requires sophisticated machinery, each of which must be properly certified and sterilized before each batch of the various products is produced. Due to the acquisition or rent-to-lease of this capital equipment, this results in high operational costs and debt levels as well.

Additionally, the FDA's requirements for maintaining an appropriately high standard of care in not just manufacturing but also packing, storage and distribution result in a substantial regulatory cost burden. This results in a high cost for the product that may affect the adoption of injectable drug delivery products. This will pose as a challenge in the growth of this market.

Other than this, the increase in needlestick injuries is another factor that can restrain the growth of the global market, as it is one of the crucial concerns of the patients opting for injectable drug delivery products.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Insights

Why is the U.S. Market Booming?

“High Frequency of Chronic Diseases”

The U.S. accounted for around 85.2% market share in the North American market in 2022, and a similar trend is expected over the forecast period.

The vast population suffering from various chronic diseases is driving the country’s demand for injectable drug delivery products. According to the findings from the Centers for Disease Control and Prevention (CDC), as of now, there are around six individuals out of any 10, who are living with any chronic disease like cancer, heart disease, or diabetes in the U.S. These factors point at the growth of the injectable drug delivery market in this country.

Will the Germany be a Lucrative Market for Injectable Drug Delivery?

“Increasing Research and Development for Injectable Drug Delivery Products”

The Germany held around 18.7% market share of the Europe market in 2022 and was valued at US$ 2.3 Bn in 2022.

The increased research and development in this country with respect to the insulin pens has made it dominant in the Europe market. ESYSTA and Pendiq are the two insulin pens that were developed and marketed by the two German companies: Emperra GmbH E-Health Technologies, and Pendiq Intelligent Diabetes Care, respectively. All this contributes to the growth of the market in Germany.

How is China Emerging as a Prominent Market for Injectable Drug Delivery?

“Rise in Geriatric Population”

China held the largest market share of about 54.7% in the East Asia market in 2022. It is set to exhibit growth with around 9.7% CAGR, throughout the forecast period.

According to findings from the WHO (2019), around 254 million people in China fell under the age group of 60 and above and 176 million people who were 65 and above. WHO has estimated this number would reach 402 million for the ones falling under the age group of 60 and above by 2040.

Growing ageing population propels demand for self-injectors. This would eventually be favorable for the growth of the China injectable drug delivery market.

Category-wise Insights

Which Product is Driving Growth of the Global Injectable Drug Delivery Market?

“Increasing Prevalence of Insulin-Dependent Diabetes”

The insulin pens segment held around 51.2% share of the total injectable drug delivery market in 2022.

Due to the increasing prevalence of insulin-dependent diabetes, the use of the insulin pen is increasing and due to the advancements in technologies, the usage has been quite convenient for patients.

According to the International Diabetes Federation Diabetes Atlas Tenth edition 2021, there were more than 1.2 million children and adolescents, under the age group of 0 to 19 years, who lived with type 1 diabetes in 2021. This estimated that there were around 541 million adults who were at the increased risk of developing type 2 diabetes. This makes insulin pens the most dominant segment among the various products of the injectable drug delivery market.

Which Technology is Driving Growth of the Global Injectable Drug Delivery Market?

“Greater Usage of Non-Smart Injectors”

The non-smart injectors segment held around 84.2% share of the total injectable drug delivery market in 2022. This segment is expected to surge at a CAGR of 8.0% over the period of 2024 to 2033.

Since the smart injectors is a recent technology, therefore the adoption rate of the non-smart injectors is higher as compared to the smart injectors. It is quite rare that the patients rely on smart injectors for the injectable drug delivery. At the current point of time, the non-smart injectors seems to be more trustworthy for the patients when it comes to delivering the insulin on a day-to-day basis.

Which Injector Poses a Greater Adoption Based on the Usage Segment?

“The Adoption of the Disposable Injectors is Higher as Compared to Reusable Injectors”

Disposable injectors held the largest share of about 59.0% with a market value of around US$ 24.5 Bn in 2022. The disposable injectors segment in this market is also expected to surge at a CAGR of 7.7% over the period of 2024 to 2033.

When it comes to healthcare settings, the disposable injectors are preferred in order to reduce the chances of infection from the used injectors, this makes the disposable injectors the dominant segment in the end user category. In case of the reusable injectors, the cost of cleaning comes along but, in case of the disposable injectors, it is used once and disposed.

Which Indication Exhibits the Highest Revenue in the Injectable Drug Delivery Market?

“Rising Prevalence of Diabetes”

Diabetes held the largest share of about 57.6% with a market value of around US$ 23.9 Bn in 2022. As compared to the other indications, diabetes is the prevalent one and the use of the injectable drug delivery is quite high for the ones suffering from insulin-dependent diabetes. As per the International Diabetes Federation, the prevalence rate of diabetes is high particularly in developing countries as compared to the developed countries. In low- and middle-income countries, three in four adults live with diabetes. This points out to the reasons why diabetes held the largest share in 2022.

Which Distribution Channel Exhibits the Highest Revenue in the Injectable Drug Delivery Market?

“Increasing Number of Patient Visits in Hospitals”

Hospital pharmacies held the largest share of about 35.6% with a market value of around US$ 14.8 Bn in 2022. Due to the increasing prevalence of various diseases, the patient flow has increasing in the hospitals. The injectable drug delivery products have become more accessible to the patients. Apart from this, the increasing number of hospitals and patient visits have contributed to make this segment as the dominant one.

Competitive Landscape

The focus of major companies is on product line expansion and growth in emerging markets. Many companies are concentrating on the creation of novel injectable medication delivery systems, while others are concentrating on regional or product portfolio expansion through acquisitions.

For instance:

  • In 2022, Novo Nordisk A/S launched its two smart insulin pens, Novopen 6 and Novopen Echo Plus in the U.K. and Ireland market.
  • In Aug 2019, Eli Lilly and Company received the FDA approval for taltz (ixekizumab) injection, which can be used for the adults suffering from active ankylosing spondylitis or radiographic axial spondyloarthritis (r-axSpA).

Similarly, recent developments have been tracked by the team at Persistence Market Research related to companies in the injectable drug delivery space, which are available in the full report.

Injectable Drug Delivery Market Scope

Attribute

Details

Forecast Period

2024-2033

Historical Data Available for

2014-2022

Market Analysis

USD Million for Value

Key Countries Covered

  • U.S.
  • Canada
  • Brazil
  • Mexico
  • Argentina
  • Germany
  • Italy
  • France
  • U.K.
  • Spain
  • BENELUX
  • Russia
  • Nordic Countries
  • India
  • Thailand
  • Indonesia
  • Malaysia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC Countries
  • Turkey
  • North Africa
  • South Africa

Key Market Segments Covered

  • Product
  • Technology
  • Usage
  • Indication
  • Distribution Channel
  • Region

Key Companies Profiled

  • Eli Lilly and Company
  • Biocon
  • Becton, Dickinson & Company
  • West Pharmaceutical Services, Inc.
  • Johnson & Johnson
  • Antares Pharma
  • AbbVie Inc.
  • Pfizer Inc.
  • Mylan N.V.
  • Vetter Pharma-Fertigung GmbH & Co.KG
  • Emperra GmbH
  • Digital Medics Pty Ltd
  • Enable Injections LLC
  • Insulet corporation
  • Consort Medical Plc.
  • Diabnext
  • Diamesco Co., Ltd
  • SCHOTT AG (Schott Kaisha Pvt. Ltd.)
  • SiO2 Medical Products
  • Integrity Bio, Inc.
  • Wilhelm Haselmeier GmbH & Co. KG
  • Tandem Diabetes Care
  • Sanofi S.A.
  • Companion Medical Inc.
  • Ypsomed
  • F. Hoffman - La Roche Ltd.
  • Novo Nordisk A/S
  • Medtronic Plc.

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Key Segments Covered in Injectable Drug Delivery Industry Research

Product:

  • Self-Injectors
    • Single Chamber Self Injectors
    • Dual Chamber Self Injectors
  • Needle Free Injectors
    • Pre Filled Needle Free Injectors
    • Fill-Able Needle free Injectors
  • Auto Injectors
    • Prefilled Auto Injectors
    • Fill-Able Auto Injectors
  • Wearable Injectors
    • Wearable Patch Injectors
    • Off-body Worn Injectors
  • Insulin Pens
    • Reusable Insulin Pens
    • Disposable Insulin Pens
    • Smart Insulin Pens

Technology:

  • Non-Smart Injectors
  • Smart Injectors
    • Artificial Intelligence (AI) and Machine Learning Integrated
    • Near Filed Communication (NFC)
    • Cloud Computing
    • Bluetooth

Usage:

  • Disposable Injectors
  • Reusable Injectors

Indication:

  • Anaphylaxis
  • Diabetes
  • Cardiovascular Diseases
  • Multiple Sclerosis
  • Rheumatoid Arthritis
  • Cancer
  • Trauma and Emergency
  • Others

Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Online Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa (MEA)

- Companies Covered in This Report -

  • Eli Lilly and Company
  • Biocon
  • Becton, Dickinson & Company
  • West Pharmaceutical Services, Inc.
  • Johnson & Johnson
  • Antares Pharma
  • AbbVie Inc
  • Pfizer Inc.
  • Mylan N.V.
  • Vetter Pharma-Fertigung GmbH & Co.KG
  • Emperra GmbH
  • Digital Medics Pty Ltd
  • Enable Injections LLC
  • Insulet corporation
  • Consort Medical Plc
  • Diabnext
  • Diamesco Co., Ltd
  • SCHOTT AG
  • SiO2 Medical Products
  • Integrity Bio, Inc.
  • Wilhelm Haselmeier GmbH & Co. KG
  • Tandem Diabetes Care
  • Sanofi S.A.
  • Companion Medical Inc.
  • Ypsomed
  • F.Hoffman - La Roche Ltd.
  • Novo Nordisk A/S
  • Medtronic Plc.

- Frequently Asked Questions -

The global market is currently valued at around US$ 41,501.1 Bn in 2022.

Sales of the market are set to witness a high growth rate of 8.4% and be valued at US$ 101,167.4 Bn by 2033.

Demand within market increased at a 7.4% CAGR from 2014 to 2022.

The U.S., China, Germany, India and Japan account for the highest share of the global market, currently holding a 52.8% market share.

The U.S. accounts for around 85.2% share of the North American market in 2022.

U.K. accounted for around 17.5% share of the European market in 2022.

The Europe market is predicted to expand at 8.2% CAGR over the forecast period.

The China market held a share of about 54.7% in the East Asia market in 2022.

The current value of the South Asia market is US$ 4,492.2 Bn for the year, 2022.

The Japan market held a share of about 36.4% in the East Asia market in 2022.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate